Though mutations directly within the PI3K pathway have not been observed in the clinic as mechanisms of acquired resistance to MET TKIs, these mutations have been observed in cases of NSCLC and, specifically, cases of METex14-positive NSCLC [139,164]; as such, their potential role in mediating treatment resistance has been evaluated. This evidence concerns the gene MET and non-small cell lung carcinoma.